These findings suggested that since KIR2DL4 functions as either an activating receptor or an inhibitory receptor, it can affect the outcome of immunotherapy through the complicated cross-talk between different immune checkpoints and cytokines in the breast cancer immune microenvironment. Here, KIR2DL4 is linked to breast cancer.